UnknownPhase 2

Identification of Compound From Brinjal Peel Extract in the Treatment of Palmar Arsenical Keratosis and Bowen's Disease

Bangladesh36 participantsStarted 2017-09-16

Plain-language summary

Arsenicosis is a major health problem in Bangladesh. Long term exposure of arsenic causes keratosis of palm which reduce working capacity of patient. It also causes invasive skin lesions like Bowen's disease which has a risk to develop squamous cell carcinoma. Brinjal peel is well known for its antioxidant and anticancer properties. So this study will be conducted to identify the compound from brinjal peel extract and to see its outcome on keratosis and Bowen's disease.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Presence of severe keratosis and/or Bowen's disease * Drinking arsenic contaminated water for at least six months * Patient voluntarily agreed to participate Exclusion Criteria: * Age less than 18 years or more than 60 years * Pregnant and nursing mother * Skin diseases like atopic dermatitis, eczema and psoriasis

What they're measuring

Keratotic nodular size and lesion size of Bowen's disease

Timeframe: 12 weeks

Trial details

NCT IDNCT03641079

SponsorBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-12

Contact for this trial

Razia Sultana, MBBS

01715995605 dr.razia999@gmail.com

View on ClinicalTrials.gov More Keratotic Nodular Size trials